Jiangbo Pharmaceuticals Inc  

(Public, OTCBB:JGBO)   Watch this stock  
Find more results for NASDAQ:JGBO
Jul 1 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 343,674.00
P/E     -
Div/yield     -
EPS     -
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '11) 2010
Net profit margin 27.93% 30.88%
Operating margin 32.91% 49.48%
EBITD margin - 51.95%
Return on average assets 8.91% 16.22%
Return on average equity 11.36% 23.10%
Employees 934 -
CDP Score - -


Middle Section, Longmao Street Area A, Laiyang Waixiangxing Industrial Park
YANTAI, SDG 265200
+86-535-7282997 (Phone)

Website links


Jiangbo Pharmaceuticals, Inc. (Jiangbo) is a holding company. Jiangbo operates, controls and owns the pharmaceutical business of Laiyang Jiangbo Pharmaceuticals Co., Ltd. (Laiyang Jiangbo). Laiyang Jiangbo researches, develops, manufactures, markets and sells pharmaceutical products and health supplements in the Peoples Republic of China. Laiyang Jiangbo pharmaceutical companies in China producing tablets, capsules, granules, syrup , mixture, pillselectuary and oral solution for both Western medical drugs and Chinese herbal-based medical drugs. Approximately 33.3% of its products are Chinese herbal-based drugs and 66.7% are Western medical drugs. During the fiscal year ended June 30, 2010 (fiscal 2010), Laiyang Jiangbo’s top four products included Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Baobaole Chewable tablets and Radix Isatidis Disperable tablets.